Enliven Therapeutics CMO sells 5,000 shares
Enliven Therapeutics’ chief medical officer Helen Louise Collins exercised stock options for 5,000 shares of common stock at $2.48 per share on July 17, 2026, then sold 5,000 shares in multiple trades at weighted average prices between $49.72 and $53.93.
Rhea-AI Filing Summary
Enliven Therapeutics’ chief medical officer Helen Louise Collins exercised stock options for 5,000 shares of common stock at $2.48 per share on July 17, 2026, then sold 5,000 shares in multiple trades at weighted average prices between $49.72 and $53.93. After the exercise, she reported directly holding 116,268 stock options. All transactions were effected under a pre-established Rule 10b5-1 trading plan adopted on October 19, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 5,000 shares ($251K approx. pre-tax spread)
Exercise and Sale
7 txns
Insider
Collins Helen Louise
Role
CHIEF MEDICAL OFFICER
Sold
5,000 shs ($263K)
Approx. gross sale proceeds
$263K
Approx. exercise cost
$12K
Approx. pre-tax spread
$251K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F1, F9 | 5,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 5,000 | $2.48 | $12K |
| Sale | Common Stock F1, F3, F2 | 231 | $50.0542 | $12K |
| Sale | Common Stock F1, F4, F2 | 459 | $51.5466 | $24K |
| Sale | Common Stock F1, F5, F2 | 2,063 | $52.3921 | $108K |
| Sale | Common Stock F1, F6, F2 | 2,184 | $53.4199 | $117K |
| Sale | Common Stock F1, F7, F8 | 63 | $53.9208 | $3K |
Holdings After Transaction:
Stock Option (right to buy) — 116,268 contracts (Direct);
Common Stock — 25,000 shares (Direct)
Footnotes (9)
- F1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
- F2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- F3. This transaction was executed in multiple trades at prices ranging from $49.72 to $50.3565. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F4. This transaction was executed in multiple trades at prices ranging from $50.85 to $51.8305. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F5. This transaction was executed in multiple trades at prices ranging from $51.8711 to $52.845. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F6. This transaction was executed in multiple trades at prices ranging from $52.8741 to $53.8708. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F7. This transaction was executed in multiple trades at prices ranging from $53.8793 to $53.93. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F8. These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- F9. All of the shares subject to this option are fully vested and exercisable as of the date hereof.
Key Figures
Options exercised: 5,000 shares
Exercise price: $2.48 per share
Shares sold: 5,000 shares
+2 more
5 metrics
Options exercised
5,000 shares
Stock options exercised into common stock on July 17, 2026
Exercise price
$2.48 per share
Conversion or exercise price of the stock option exercised on July 17, 2026
Shares sold
5,000 shares
Total Enliven Therapeutics common shares sold in multiple transactions on July 17, 2026
Sale price range
$49.72–$53.93 per share
Weighted average sale price ranges disclosed across sale footnotes F3–F7
Options held after exercise
116,268 options
Total stock options reported following the derivative transaction
Key Terms
Rule 10b5-1 trading plan, restricted stock units (RSUs), weighted average sale price, contingent right
4 terms
Rule 10b5-1 trading plan regulatory
"were effected pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units (RSUs) financial
"Certain of these securities are restricted stock units (RSUs). Each RSU"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
contingent right financial
"Each RSU represents a contingent right to receive one share"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Enliven Therapeutics (ELVN) report for Helen Collins?
Helen Louise Collins reported exercising 5,000 stock options at $2.48 per share and selling 5,000 common shares of Enliven Therapeutics on July 17, 2026. The sales occurred through multiple trades at weighted average prices between $49.72 and $53.93 per share.
What stock options did Helen Collins exercise at Enliven Therapeutics (ELVN)?
Collins exercised a stock option for 5,000 shares of Enliven Therapeutics common stock at an exercise price of $2.48 per share. Footnotes indicate all shares under this option were fully vested and exercisable, and the option has an expiration date of June 17, 2031.
Was the Enliven Therapeutics (ELVN) insider trading done under a Rule 10b5-1 plan?
Yes. Footnote F1 states that the option exercise and related sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Helen Collins on October 19, 2025. Such plans pre-arrange trading, reducing the informational value of transaction timing.
How many Enliven Therapeutics (ELVN) stock options does Helen Collins hold after these transactions?
Following the reported option exercise, Collins reported holding 116,268 stock options directly. This figure comes from the derivative transaction line showing total stock options following the transaction and reflects her remaining option position as disclosed in this Form 4.
What role does Helen Collins hold at Enliven Therapeutics (ELVN)?
Helen Louise Collins is reported as the Chief Medical Officer of Enliven Therapeutics. The Form 4 identifies her as an officer of the company with that title, and the transactions disclosed relate to her holdings and option awards in the issuer’s equity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
